REACTION
MECHANISM · TIMING
CLINICAL PICTURE
PREVENT · TREAT
IV · haptens (nickel, poison ivy urushiol, neomycin, latex additives) · 48–72 h
Itchy, vesicular, sharply bordered rash where contact occurred
Patch test · avoid, topical steroids
Tuberculin (PPD) reaction
IV · memory Th1 cells · 48–72 h
Induration at injection site
Anergy in AIDS, sarcoid, steroids → false negative
Granulomatous inflammation
IV · Th1 + IFN-γ + TNF-α → epithelioid macrophages, giant cells
TB, sarcoidosis, leprosy, Crohn, fungi
TNF blockers break granulomas
IV · direct cytotoxicity
Type 1 diabetes (β cells), Hashimoto, viral hepatitis damage, SJS/TEN, acute graft rejection
—
IV · drug-specific T cells (HLA-linked)
SJS/TEN (sulfonamides, allopurinol, carbamazepine, lamotrigine), DRESS (fever, rash, eosinophilia, organ involvement 2–8 weeks)
Stop drug · HLA-B*58:01 (allopurinol), B*15:02 (carbamazepine)
Acute hemolytic transfusion reaction
II · preformed anti-A/anti-B (IgM) → intravascular complement lysis · minutes
Fever, chills, flank pain, hypotension, hemoglobinuria, DIC, AKI
Stop transfusion, fluids · clerical error usual cause · ⁺ direct Coombs, ↓ haptoglobin
Febrile non-hemolytic reaction
Cytokines from donor leukocytes accumulated in stored blood · within 1–6 h
Fever, chills; no hemolysis
Most common · leukoreduced products, antipyretics
Allergic transfusion reaction
I · recipient IgE to donor plasma proteins
Urticaria, itching
Antihistamine; may continue
Anaphylactic transfusion reaction
I · IgA-deficient recipient with anti-IgA
Shock, angioedema within minutes
Epinephrine · future: washed or IgA-deficient products
Donor anti-HLA/anti-neutrophil antibodies activate recipient neutrophils in lung · within 6 h
Hypoxemia, bilateral infiltrates, fever, hypotension; normal PCWP
Supportive · defer female multiparous plasma donors
Volume overload · within hours
Pulmonary edema, hypertension, ↑ BNP, JVD
Slow rate, diuretics
Delayed hemolytic reaction
II · anamnestic IgG to minor antigens (Kidd, Rh) · 2–10 days
Mild fever, falling Hb, jaundice; extravascular
New ⁺ antibody screen, ⁺ DAT
Transfusion-associated GVHD
Donor T cells attack an immunocompromised or HLA-similar recipient · 1–6 weeks
Rash, diarrhea, hepatitis, pancytopenia (marrow attacked) — often fatal
Irradiate products for at-risk patients